Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both ...
Global and Fortune 500 companies and world-class real estate portfolios recognized for catalyzing people-first places and organizations in 2024Barclays, CBRE, Cisco, Citi Global, EDGE Technologies, Em ...
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...
(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its ...
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...
Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.
This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback